Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
|Videos|November 4, 2021
New Ways to Monitor Glucose, Early Treatment in Hopes for Future of Advanced CKD
Galindo hopes that less patients will be diagnosed with advanced chronic kidney disease if we use the right glucose-lowering agents in the earliest stages.
Advertisement
Pharmacy Times spoke to Rodolfo Galindo, MD, associate professor at the Emory School of Medicine, about his session at the ASN 2021 conference titled "Use of Glucose-Lowering Agents and Glycemic Monitoring in Advanced CKD.”
Galindo hopes that less patients will be diagnosed with advanced chronic kidney disease if we use the right glucose-lowering agents in the earliest stages.
Advertisement
Related to this article
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
Preparing Pharmacists for Psychedelic Medicine
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5